{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=55", "query": { "intervention": "Matching Oral Placebo", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 3459, "total_pages": 346, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T23:32:54.059Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04115839", "title": "Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2019-11-13", "completion_date": "2021-03-18", "has_results": true, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 22, "location_summary": "Covina, California • DeBary, Florida • Miami, Florida + 19 more", "locations": [ { "city": "Covina", "state": "California" }, { "city": "DeBary", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115839" }, { "nct_id": "NCT01241669", "title": "Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "E5555", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 104, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241669" }, { "nct_id": "NCT06679062", "title": "Suvorexant for Treatment of AUD and PTSD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder (AUD)", "Post Traumatic Stress Disorder (PTSD)", "Insomnia" ], "interventions": [ { "name": "Suvorexant", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pharmacotherapies for Alcohol and Substance Use Disorders Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 76, "start_date": "2025-07-16", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679062" }, { "nct_id": "NCT01594827", "title": "Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Inhaled Vancomycin", "type": "DRUG" }, { "name": "Placebo (Sterile Water)", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Trimethoprim/Sulfamethoxazole (TMP/SMX)", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Mupirocin Intranasal Creme", "type": "DRUG" }, { "name": "4% chlorhexidine gluconate liquid skin cleanser", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 29, "start_date": "2012-10", "completion_date": "2017-12-30", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Cleveland, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594827" }, { "nct_id": "NCT05763576", "title": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "RO7565020", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Nucleos(t)ide analogue (NUC) treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2023-04-28", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05763576" }, { "nct_id": "NCT04044664", "title": "Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-Traumatic Stress Disorder" ], "interventions": [ { "name": "Placebo oral capsule", "type": "DRUG" }, { "name": "NYX-783", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptinyx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 160, "start_date": "2019-01-25", "completion_date": "2020-08-05", "has_results": true, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 37, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044664" }, { "nct_id": "NCT07128199", "title": "A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer", "Adjuvant", "Post-surgical", "EGFR", "Exon 20", "Early Stage Lung Cancer", "Uncommon EGFR Mutations", "NSCLC, Early Stage" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" }, { "name": "Zipalertinib Matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-12-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Duarte, California • Irvine, California + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128199" }, { "nct_id": "NCT01656187", "title": "Attenuation of Corticosteroid Induced Hippocampal Changes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Organic Memory Impairment" ], "interventions": [ { "name": "Memantine 10 mg capsule", "type": "DRUG" }, { "name": "Memantine-matched Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 46, "start_date": "2012-01", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2019-03-29", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656187" }, { "nct_id": "NCT02511106", "title": "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB-IIIA Non-small Cell Lung Carcinoma" ], "interventions": [ { "name": "AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Placebo AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Open-label AZD9291 80 mg/40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 682, "start_date": "2015-10-21", "completion_date": "2029-01-31", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 23, "location_summary": "Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511106" }, { "nct_id": "NCT06721871", "title": "Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Microvillus Inclusion Disease", "Congenital Disorders", "Rare Diseases" ], "interventions": [ { "name": "Crofelemer Powder for Oral Solution", "type": "DRUG" }, { "name": "Placebo Powder for Oral Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Napo Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 6, "start_date": "2025-05-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-17T23:32:54.059Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06721871" } ] }